产品概述
| 产品名称（Product Name） | p16 (phospho Ser326) Rabbit Polyclonal Antibody |
| 描述（Description） | Rabbit Polyclonal Antibody |
| 宿主（Host） | Rabbit |
| 应用（Application） | WB,IHC-P,IF-P,IF-F,ICC/IF,ELISA |
| 种属反应性（Reactivity） | Human,Rat,Mouse |
产品性能
| 偶联物（Conjugation） | Unconjugated |
| 修饰（Modification） | Phospho Antibody |
| 同种型（Isotype） | IgG |
| 克隆（Clonality） | Polyclonal |
| 形式（Form） | Liquid |
| 存放说明（Storage） | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 储存溶液（Buffer） | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
| 纯化方式（Purification） | Affinity purification |
免疫原
| 基因名（Gene Name） | CDKN2A |
| 别名（Alternative Names） | CDKN2A; CDKN2; MTS1; Cyclin-dependent kinase inhibitor 2A; isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A |
| 基因ID（Gene ID） | 1029 |
| 蛋白ID（SwissProt ID） | P42771 |
产品应用
| 稀释比（Dilution Ratio） | WB 1:500-1:2000, IHC-P 1:100-1:300, ELISA 1:5000, IF-P/IF-F/ICC/IF 1:50-200 |
| 蛋白分子量（Molecular Weight） | 20kDa |
研究背景
alternative products:Isoform 1 and isoform 4 arise due to the use of two alternative first exons joined to a common exon 2 at the same acceptor site but in different reading frames, resulting in two completely different isoforms,disease:Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.,disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.,disease:Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.,disease:Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].,disease:Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.,function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.,function:Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.,online information:Database of CDKN2A germline and somatic variants,online information:P16INK4a entry,polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Does not interact with cyclins, CDC2, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1. Interacts with CDKN2AIP and E4F1.,subunit:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4.,tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.,alternative products:Isoform 1 and isoform 4 arise due to the use of two alternative first exons joined to a common exon 2 at the same acceptor site but in different reading frames, resulting in two completely different isoforms,disease:Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.,disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.,disease:Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.,disease:Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].,disease:Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.,function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.,function:Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.,online information:Database of CDKN2A germline and somatic variants,online information:P16INK4a entry,polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Does not interact with cyclins, CDC2, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1. Interacts with CDKN2AIP and E4F1.,subunit:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4.,tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.,
研究领域
关键字： CDKN2A;p16;(phospho;Ser326);Rabbit;Polyclonal;Antibody;一抗
武汉恩玑生命科技有限公司（EnkiLife）是一家深耕生命科学，专注细胞生物学和免疫学科研试剂的研发、生产与销售的生物技术企业，在全球100多个国家和地区开展业务，致力于为科研工作者提供高质量的产品和卓越的客户服务，推动生命科学的发展。
EnkiLife的产品线涵盖细胞系、原代细胞、细胞培养基、血清、细胞检测试剂盒、重组靶点蛋白、细胞因子、重组抗体、ELISA试剂盒、生化试剂盒等，并提供技术服务与定制开发，覆盖了生命科学研究的各大关键领域，包括细胞生物学、癌症、免疫学、神经科学、心血管疾病、干细胞、表观遗传学、内分泌、蛋白质组学、代谢组学等，全方位满足您的实验需求，让您享受科研的乐趣！
公司现已建立四大技术平台：
EnCyto?细胞培养及检测平台：拥有细胞系库（500+）、原代细胞库（500+）、基础培养基和完全培养基（1200+）
EnkiPro?重组蛋白平台：现货产品2000+，可提供定制化表达服务
EnAb?重组抗体平台：重组兔单抗（3000+），可提供定制化和标记服务
EnKits?试剂盒开发平台：可提供优质的ELISA试剂盒、配套试剂、抗体对、生化试剂盒等相关产品
EnkiLife在生产管理方面引入ISO9001质量管理体系和信息化、自动化的管理工具，拥有高效稳定的交付能力，与全球知名品牌建立了紧密的合作。
EnkiLife始终坚持以技术创新为驱动，以匠心铸就品质，以品质服务客户。
我们期待与更多的全球科研工作者和企业携手合作，共同推动生命科学领域的进步与发展。